The Surrey Clinical Research Centre was recently at the centre of an international effort with European Commission funding to design and test a vaccine to prevent HIV/AIDS. The vaccine employed several highly innovative concepts including nasal delivery to produce strong genital tract immunity, liposomal formulation, and an uniquely designed active component to make virus-blocking antibodies. The SCRC conducted the first in human clinical trial of this product, drawing on its extensive expertise in translational medicine, mucosal immunology, and Phase 1 trial accreditation.
We are excited to announce the commencement of a cutting edge Phase 1 study deploying a live genetically modified virus to treat cancer patients with advanced solid tumours. In addition to trials using oncolytic viruses we also work on other studies translating innovative anti-cancer strategies into clinical trials including (a) novel therapies in which cancer genes are switched off (transcriptional targeting) with the aim of causing cancer-specific cell death, and b) the study of certain gene products as potential tumour associated antigens which can be targeted by cancer vaccines.
We are delighted to announce that Surrey Clinical Research Centre has been awarded MHRA Phase 1 Standard and Supplementary Accreditation as of 1 August 2012. We are one of only two non-commercial centres to achieve this accreditation status which enables us to carry out clinical trials with compounds at all levels of risk. Furthermore, it demonstrates the quality of our work which is underpinned by a team of well-trained and highly experienced staff.